4.62

2.74% -0.13

Sagimet Biosciences Inc (SGMT)

Overview News Price History Discussions Forecast

Sagimet Biosciences Inc stock is currently priced at $4.62, with a 24-hour trading volume of 268.37K. It has seen a -2.74% decreased in the last 24 hours and a +13.51% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $4.79 pivot point. If it approaches the $4.52 support level, significant changes may occur.

Previous Close:

$4.75

Open:

$4.71

24h Volume:

268.37K

Market Cap:

$147.44M

Revenue:

Net Income/Loss:

$-27.88M

P/E Ratio:

-4.0059

EPS:

-1.1533

Net Cash Flow:

$-23.77M

1W Performance:

+4.05%

1M Performance:

+13.51%

6M Performance:

+56.08%

1Y Performance:

+0.00%

1D Range:

$4.54

$4.76

52W Range:

$2.13

$20.71

Sagimet Biosciences Inc Stock (SGMT) Company Profile

Name

Sagimet Biosciences Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

650-561-8600

Address

155 Bovet Road, Suite 303, San Mateo

Employee

Twitter

Next Earnings Date

Latest SEC Filings

SGMT's Discussions on Twitter

Sagimet Biosciences Inc Stock (SGMT) Latest News

Sagimet Biosciences (NASDAQ:SGMT) Price Target Cut to $23.00 by Analysts at The Goldman Sachs Group - Defense World

Defense World

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $39.60 Average PT from Analysts - MarketBeat

MarketBeat

Sagimet Biosciences (NASDAQ:SGMT) PT Lowered to $23.00 - MarketBeat

MarketBeat

Sagimet Biosciences' (SGMT) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

MarketBeat

Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday

Benzinga

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver ... - GlobeNewswire

GlobeNewswire

Sagimet Biosciences Inc Stock (SGMT) Financials Data

Sagimet Biosciences Inc (SGMT) Net Income 2024

SGMT net income (TTM) was -$27.88 million for the quarter ending December 31, 2023, a +8.60% increase year-over-year.

Sagimet Biosciences Inc (SGMT) Cash Flow 2024

SGMT recorded a free cash flow (TTM) of -$23.77 million for the quarter ending December 31, 2023, a +2.96% increase year-over-year.

Sagimet Biosciences Inc (SGMT) Earnings per Share 2024

SGMT earnings per share (TTM) was -$1.3091 for the quarter ending December 31, 2023, a +4.82% growth year-over-year.

Sagimet Biosciences Inc Stock (SGMT) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Happel David	President & CEO	Dec 07 '23	Buy	4.10	1,600	6,560	627,100
Happel David	President & CEO	Nov 16 '23	Buy	2.35	590	1,386	590
Kemble George	Executive Chairman	Sep 07 '23	Option Exercise	0.79	5,630	4,448	5,630
SEIDENBERG BETH C	Director	Jul 18 '23	Buy	16.00	46,875	750,000	46,875
NEW ENTERPRISE ASSOCIATES 13 L	10% Owner	Jul 18 '23	Buy	16.00	30,000	480,000	3,850,275
NEW ENTERPRISE ASSOCIATES 13 L	10% Owner	Jul 18 '23	Sale	16.00	662	10,592	3,820,275

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.